Article | May 18, 2023

In Silico Modeling Unveils A New Era In Rare Disease Drug Development

Source: Premier Research
GettyImages-597935610 cell and gene

In silico clinical trials have been recognized by the FDA as useful tools in advancing personalized treatment and streamlining randomized controlled trials. Recent progress in computational methods has been powered by advancements in computing technologies and the advent of artificial intelligence and machine learning.

Thanks to these developments in the rare disease space, the industry has witnessed novel opportunities to evaluate extensive databases and integrate information effectively. In this article, the author emphasizes the application of in silico trials as an exciting development in the pursuit of developing innovative therapies for rare diseases.

By leveraging these technologies, discover how researchers can optimize the drug development process and bring forth potential treatments more efficiently and tailored to rare disease populations.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene